How does eculizumab compare to other complement inhibitors?

Feb 7, 2019 ... Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study The SOLIRIS Infusion Finder provides access to a locator tool, which shows sites providing infusion services. Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. It inhibits the cleavage of C5 into C5a and C5b and hence inhibits ... Apr 7, 2025 ... ... Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris ® in the U.S. Teva and Samsung Bioepis entered into ... Nov 18, 2022 ... Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b.